Tim Raine, MB, BChir, PhD

Addenbrooke’s Hospital
Cambridge, UK

Mark Silverberg, MD, PhD, FRCP(C)

Mount Sinai Hospital
Toronto, Canada

Saturday, November 20, 2021

12:30 pm - 1:15 pm

Concurrent Session #1:

The evolution of an endpoint – a look into trials from past and present and changing approaches to steroid-free remission

Learning Objectives:

  • Examine the historical role of corticosteroid in IBD treatment
  • To  deliberate on the evolution of endpoints in trials to steroid free remission
  • To discuss best standard of care currently for use of corticosteroids

Tim Raine is a consultant gastroenterologist and clinical lead for the inflammatory bowel disease (IBD) service at Addenbrooke's hospital, UK. His research is focused on understanding the regulation of the gastrointestinal immune system, in particular in the context of IBD. He is a member of the European Crohn's and Colitis Organisation (ECCO and is current chair-elect of the Guidelines Committee, responsible for co-ordinating development and updating of the influential ECCO IBD guidelines. He is an author/project lead on several sets of ECCO guidelines on management of IBD and on the BSG guidelines for the management of IBD.

Mark S. Silverberg MD, PhD, is a Professor in the Department of Medicine at the University of Toronto and Staff Gastroenterologist at Mount Sinai Hospital. He leads an active research program focused on elucidating the genetic and microbial contributors to the pathogenesis of IBD and to identify biomarkers relevant to its clinical course. Dr. Silverberg is also engaged in educating health care professionals on IBD through his roles as Founder and Past Director of the Advanced IBD Fellowship Program at Mount Sinai Hospital for 15 years and as co-director of both the Canadian GI Fellows Program in IBD and the Great Lakes IBD Forum. He is a member of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD), Past Chair of the Scientific and Medical Advisory Council of Crohn’s and Colitis Canada and of the IMIBD Section of the AGA Council. He is the Founder and Medical Director of the Toronto Immune and Digestive Health Institute, a stand alone outpatient centre for integrative IBD care and clinical trials.

Sponsored by: